Comparative Pharmacology
Head-to-head clinical analysis: FERIDEX I V versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERIDEX I V versus SCANLUX 300.
FERIDEX I.V. vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FERIDEX I.V. (ferumoxytol) is an iron oxide nanoparticle coated with a carbohydrate shell. After intravenous administration, ferumoxytol is taken up by macrophages of the reticuloendothelial system, releasing iron into the intracellular iron pool. Iron is transported by transferrin to erythroid precursor cells for hemoglobin synthesis, thereby replenishing iron stores.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
15 mg/kg intravenous infusion over 4 hours, maximum single dose 1200 mg, repeat after 72 hours if ferritin <100 ng/mL and transferrin saturation <20%.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal elimination half-life (t½) of ferric carboxymaltose is approximately 7-12 hours (mean ~9 hours) in iron-deficient patients. Clinical context: The iron is rapidly delivered to the reticuloendothelial system for processing; reticulocyte response is seen within 1-2 weeks. The half-life reflects clearance of the complex from plasma, not iron turnover.
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Primarily eliminated via hepatobiliary and fecal routes as intact complex; renal excretion is minimal (<1%) for iron, but ferric carboxymaltose complex is not dialyzable. In patients with iron deficiency, ~50-60% of administered iron is incorporated into hemoglobin and red blood cells within 2-4 weeks; the remainder is stored as ferritin and hemosiderin. The carboxymaltose moiety is partially metabolized and excreted via urine and feces.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent